澳優(01717.HK)一季度經調整淨利潤增長11%至3.31億元 自家品牌配方牛奶粉業務收入升36.5%
格隆匯5月11日丨澳優(01717.HK)發佈公吿，截至2021年3月31日止3個月，公司收入21.83億元人民幣，同比增長12.9%；毛利11.16億元，同比增長7.2%；公司擁有人應占淨利潤3.31億元，同比增長22.9%；經調整公司擁有人應占淨利潤3.31億元，同比增長11%。
自家品牌配方牛奶粉業務表現依然理想，錄得收入人民幣10.53億元，同比增長36.5%。尤其是海普諾凱1897業務單元於2021年第一季錄得收入人民幣7.18億元，同比增長58.7%，繼續為集團增長最快的業務單元。
集團在中國的自家品牌配方羊奶粉業務亦於2021年第一季復甦，錄得收入人民幣8.35億元，與上一個回顧季度環比增長29.7%。公司認為，自家品牌配方奶粉業務復甦且持續增長歸功於集團迅速調整策略以應對市場轉變，加上堅持擁抱母嬰店渠道，以高頻次高質量消費者活動賦能渠道。
集團積極響應市場發展，繼續於此一範疇大力推動研發投資。集團的努力得到理想結果。中國國家市場監督管理總局於2021年4月25日批准集團註冊為乳糖不耐症嬰兒而設的特殊醫學用途嬰兒無乳糖配方食品。同日，中國國家衞生健康委員會批准集團聯營公司錦旗生物集團(Bioflag International Corporation)就MP108鼠李糖乳桿菌(lactobacillus rhamnosusMP108)（一種新食材菌株，有助預防多種小兒炎症）在中國使用提交的申請。鼠李糖乳桿菌乃首支由中國公司開發並獲准在中國用於嬰幼兒食品的菌株，標誌着中國市場在此方面的一大突破。集團營養品業務方面，過去大部分Nutrition Care的營養品均於澳洲生產，但受到供應能力的限制。
為解決供應能力的限制及更有效地支持集團在中國市場的發展，集團決定將Nutrition Care部份產品轉由中國進行生產。相應技術檢核已在進行，公司將於本年第二季開始在中國生產部分營養品。集團未來將繼續以科學化的方式審慎推動業務發展和增長，緊貼最新趨勢，將產品組合從嬰兒拓展至兒童及成人營養品，進一步促進消費者健康成長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
